FDA Approved: PROLIA — Supplemental Application (Amgen, Inc)

View source ↗

Summary

FDA approved a supplemental application for Prolia (denosumab) submitted by Amgen, related to the drug's labeling/indication via a supplemental filing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Prolia (denosumab)

Snippet

SUPPL AP for PROLIA (DENOSUMAB)